Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Rosenmann is active.

Publication


Featured researches published by David Rosenmann.


Chest | 1990

Use of Pulmonary Artery Catheters in Patients with Acute Myocardial Infarction

Monty M. Zion; Jonathan Balkin; David Rosenmann; Uri Goldbourt; Henrietta Reicher-Reiss; Elieser Kaplinsky; Solomon Behar

This study analyzes the use of PAC in a registry comprising 5,841 hospitalized patients with AMI. A total of 371 patients received PAC. In-hospital mortality was higher in patients with CHF who received PAC, while there was no difference in patients with cardiogenic shock or persistent hypotension. Mortality in patients receiving PAC was higher irrespective of the presence or absence of pump failure. A separate analysis of discharge summaries of 364 patients with CHF showed that PAC was used more frequently in sicker patients and that when severity of CHF was assessed, no difference in mortality was found in patients with mild or moderate CHF. We conclude that while a higher in-hospital mortality is found in patients receiving PAC, this excess is likely related to difference in severity of CHF, which had not been assessed in every individual. It is unlikely that PAC increases mortality.


Journal of Neuropathology and Experimental Neurology | 2009

Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.

Moran Boimel; Nikolaos Grigoriadis; Athanassios Lourbopoulos; Olga Touloumi; David Rosenmann; Oded Abramsky; Hanna Rosenmann

Abstract Statin treatment has been associated with a reduced risk of Alzheimer disease and decreased amyloid deposition in mouse models. No animal studies have reported effects of statins on tau aggregates and neurofibrillary tangles (NFTs), the pathological hallmarks of Alzheimer disease that correlate with dementia. We investigated the effect of statins on NFTs in a transgenic mouse tauopathy model and found the following: 1) 1-month treatment with the blood-brain barrier-permeable agent simvastatin in normocholesterolemic aged mice significantly reduced the NFT burden and decreased lectin-positive microglia; 2) simvastatin significantly decreased NFTs and improved T-maze performance in young animals treated for 8 months; 3) treatment of hypercholesterolemic mice for 5 months with blood-brain barrier-impermeable atorvastatin markedly reduced the NFT burden and decreased lectin-positive microglia; 4) nonstatin cholesterol-lowering strategies showed a modest NFT decrease compared with statin treatment; and 5) there was a positive correlation between microglial and NFT burden (r = 0.8). Together, these results suggest that statins reduce NFT burden irrespective of blood-brain barrier permeability at both early and late ages in long- and short-term treatment paradigms and under normocholesterolemic and hypercholesterolemic conditions. The decrease in microglia, coupled with the limited effect of nonstatin cholesterol lowering, suggests that the anti-NFT effect of statins may be related to their anti-inflammatory and not necessarily to their cholesterol-lowering properties. Statins may provide therapy against NFTs in tauopathies, particularly when NFTs are the major neuropathologic component.


Chest | 1990

Use of pulmonary artery catheters in patients with acute myocardial infarction. Analysis of experience in 5,841 patients in the SPRINT Registry. SPRINT Study Group.

Monty Zion; Jonathan Balkin; David Rosenmann; Uri Goldbourt; Henrietta Reicher-Reiss; Elieser Kaplinsky; Solomon Behar

This study analyzes the use of PAC in a registry comprising 5,841 hospitalized patients with AMI. A total of 371 patients received PAC. In-hospital mortality was higher in patients with CHF who received PAC, while there was no difference in patients with cardiogenic shock or persistent hypotension. Mortality in patients receiving PAC was higher irrespective of the presence or absence of pump failure. A separate analysis of discharge summaries of 364 patients with CHF showed that PAC was used more frequently in sicker patients and that when severity of CHF was assessed, no difference in mortality was found in patients with mild or moderate CHF. We conclude that while a higher in-hospital mortality is found in patients receiving PAC, this excess is likely related to difference in severity of CHF, which had not been assessed in every individual. It is unlikely that PAC increases mortality.


Pacing and Clinical Electrophysiology | 2009

Tricuspid Incompetence Following Permanent Pacemaker Implantation

Marc W. Klutstein; Jonathan Balkin; Adi Butnaru; Michael Ilan; Amnon Lahad; David Rosenmann

Aim: Severe tricuspid insufficiency (TI) after permanent pacemaker implantation (PPI) has been described in small series of patients, though its incidence is not known.


The Cardiology | 1988

Influence of Chronic Diuretic Therapy on Serum, Lymphocyte and Erythrocyte Potassium, Magnesium and Calcium Concentrations

Abraham S. Abraham; Zion Meshulam; David Rosenmann; Uri Eylath

Serum, lymphocyte and erythrocyte potassium, magnesium and calcium concentrations were measured in 31 patients with congestive cardiac failure and 14 patients with mild noncomplicated hypertension, who had been receiving either furosemide or chlorothiazide (with or without potassium supplementation) or a combination of hydrochlorothiazide and amiloride for more than 6 months. Lymphocyte potassium concentrations (pmol/100 cells +/- SE) were as follows: controls 18.1 +/- 1.5, furosemide 14.1 +/- 0.9 (p less than 0.001), furosemide + potassium 12.3 +/- 0.7 (p less than 0.001), chlorothiazide 13.1 +/- 1.0 (p less than 0.001) and hydrochlorothiazide + amiloride 18.6 +/- 0.7 (p = NS). There was a statistically significant relationship between the number of months the patients had been on diuretics and their lymphocyte potassium concentrations. Serum electrolytes, apart from the group receiving chlorothiazide who showed a significant fall in serum K, were unchanged.


American Heart Journal | 1998

Diagnostic value of 12-lead electrocardiogram during dobutamine echocardiographic studies

Joseph Shaheen; David Luria; Marc W. Klutstein; David Rosenmann; Dan Tzivoni

BACKGROUNDnThe diagnostic value of 12-lead electrocardiography during dobutamine stress echocardiography (DSE) is not well documented.nnnMETHODS AND RESULTSnWe reviewed the records of 116 patients referred for DSE and coronary angiography, 52 of whom were excluded because of abnormal ST segment or inadequate DSE. Of the analyzed 65 patients, 42 had angiographic evidence of significant coronary disease, 41 had evidence of ischemia according to the echocardiographic criteria, and 30 had ST changes during the study. DSE had sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 88%, 81%, 90%, and 78%, respectively. Twelve-lead electrocardiography had sensitivity, specificity, PPV, and NPV of 52%, 64%, 72%, and 41%, respectively. NPV increased to 92% in patients with negative DSE and negative ST changes. PPV increased to 95% if both DSE and 12-lead electrocardiographic ischemic changes were observed.nnnCONCLUSIONSnTwelve-lead electrocardiography has an incremental diagnostic value when used during DSE.


The Cardiology | 1988

Lymphocyte Potassium and Magnesium Concentrations as Prognostic Factors after Acute Myocardial Infarction

Abraham S. Abraham; David Rosenmann; Monty M. Zion; Uri Eylath

215 patients admitted with acute myocardial infarction were prospectively evaluated for prognostic factors. When lymphocyte potassium concentration increased by up to twofold of normal, a high lymphocyte magnesium concentration was associated with a good prognosis. However, when the increase in lymphocyte potassium concentration was greater than twofold, the presence of a high lymphocyte magnesium made no difference to mortality. Age, the female sex, anterior wall infarction, high serum enzymes, heart failure, diabetes mellitus in females and serious arrhythmias were all bad prognostic signs.


American Journal of Cardiology | 2015

Comparison of the Usefulness of Heart Rate Variability Versus Exercise Stress Testing for the Detection of Myocardial Ischemia in Patients Without Known Coronary Artery Disease

Ronen Goldkorn; Alexey Naimushin; Nir Shlomo; Ariella Dan; Dan Oieru; Israel Moalem; Eli Rozen; Ilan Gur; Jacob Levitan; David Rosenmann; Yakov Mogilewsky; Robert Klempfner; Ilan Goldenberg

Heart rate variability (HRV) has been shown to be attenuated in patients with coronary artery disease (CAD) and may, therefore, be possibly used for the early detection of myocardial ischemia. We aimed to evaluate the diagnostic yield of a novel short-term HRV algorithm for the detection of myocardial ischemia in subjects without known CAD. We prospectively enrolled 450 subjects without known CAD who were referred to tertiary medical centers for exercise stress testing (EST) with single-photon emission computed tomography myocardial perfusion imaging (MPI). All subjects underwent 1-hour Holter testing with subsequent HRV analysis before EST with MPI. The diagnostic yield of HRV analysis was compared with EST, using MPI as the gold standard for the noninvasive detection of myocardial ischemia. All subjects had intermediate pretest probability for CAD. Mean age was 62xa0years, 38% were women, 51% had hypertension, and 25% diabetes mellitus. HRV analysis showed superior sensitivity (77%) compared with standard EST (27%). After multivariate adjustment, HRV was independently associated with an 8.4-fold (p <0.001) increased likelihood for the detection of myocardial ischemia by MPI, whereas EST did not show a statistically significant association with a positive MPI (odds ratio 2.1; pxa0= 0.12). Of subjects who were referred for subsequent coronary angiography, the respective sensitivities of HRV and EST for the detection of significant CAD were 73% versus 26%. Our data suggest that HRV can be used as an important noninvasive technique for the detection of myocardial ischemia in subjects without known CAD, providing superior sensitivity to conventional EST in this population.


The Cardiology | 1988

Effects of Enalapril on Lymphocyte Sodium, Potassium, Magnesium and Calcium Levels in Patients with Severe Congestive Heart Failure

Abraham S. Abraham; Jonathan Balkin; David Rosenmann; Barry A. Brooks; Uri Eylath; Monty M. Zion

Fifteen patients (median age 73 years) with severe congestive heart failure were treated with Enalapril for a total of 12 weeks with a significant improvement in their right atrial pressures and in their functional state. Renal function, serum potassium, magnesium and calcium levels were unchanged. Lymphocyte sodium, potassium and calcium levels were generally lower than control values throughout the study but these differences were only statistically significant early in the study. Lymphocyte magnesium levels were unchanged. These findings are in contrast to those previously reported in the literature for such patients treated with conventional diuretics.


JAMA Internal Medicine | 1987

Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction.

Abraham S. Abraham; David Rosenmann; Mordechai R. Kramer; Jonathan Balkin; Monty M. Zion; Hannan Farbstien; Uri Eylath

Collaboration


Dive into the David Rosenmann's collaboration.

Top Co-Authors

Avatar

Jonathan Balkin

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Abraham S. Abraham

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Uri Eylath

Shaare Zedek Medical Center

View shared research outputs
Top Co-Authors

Avatar

Marc W. Klutstein

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Monty M. Zion

University of the Witwatersrand

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Monty M. Zion

University of the Witwatersrand

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Adi Butnaru

Hebrew University of Jerusalem

View shared research outputs
Researchain Logo
Decentralizing Knowledge